Haemonetics Shares Plunged: What You Need to Know (HAE)

Haemonetics Shares Plunged: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Haemonetics (NYSE: HAE ) are taking it on the chin today, down as much as 13% earlier in the trading session following the company's first-quarter earnings report.

So what: Haemonetics manufacturers and provides devices used in the collection of blood -- and based on today's results, I'd have to say that most of that blood was from Haemonetics' shareholders. Revenue for the quarter actually squeaked by consensus estimates ($170.6 million versus $170 million), but earnings fell well short of expectations, $0.65 versus $0.78. Haemonetics blamed a recall on nearly 3,000 models of its proprietary blood-collecting device OrthoPAT as the reason for the shortfall. Full-year guidance was also reduced from a range of $3.50-$3.62 to $3.35-$3.45, yet revenue growth projections remain unchanged at 4%-6%.

Now what: Haemonetics is a mixed bag. On one hand, the company has an impeccable balance sheet ripe with cash and a proprietary product that is a cash cow. On the flipside, for having such an in-demand product, it's almost disappointing that the company's growth rate is stuck in the 4%-6% range. Even at just 15 times forward earnings, the company doesn't seem all that inexpensive when you consider the snail's pace it's currently growing at. For now, I'd consider passing on Haemonetics, but it definitely could be worth a spot on your watchlist.

Craving more input? Add Haemonetics to your watchlist!

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.